BGIN's Mining Machine Brand ICERIVER® ALEO AE3 Selected as One of CoinCodex's "Top 8 ASIC Mining Machines"
BlockBeats News, March 16th, the well-known crypto media CoinCodex recently selected the "8 Top ASIC Miners," with the ICERIVER® ALEO AE3 miner successfully making the cut.
According to the CoinCodex report cited, the ICERIVER® ALEO AE3 is a dedicated ASIC miner designed for the zkSNARK algorithm, specifically optimized for Aleo blockchain mining. It boasts a maximum hash rate of 2GH/s (±5%), making it a high-performance solution for miners targeting Aleo's privacy-centric blockchain.
Further details from the selection report indicate that the AE3 has a power consumption of 3400W, with an efficiency of 1.7 J/MH. The device is set to be released in November 2025, operates at a noise level of 75dB, and requires a 200-250V power supply. Its stable and durable structure, along with enterprise-grade specifications, make it an ideal choice for a professional mining setup.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
